|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.10 CNY | -0.66% |
|
-6.85% | +0.89% |
| Jan. 12 | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | MT |
| Jan. 12 | Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation | MT |
ETFs positioned on Jiangsu Hengrui Pharmaceuticals Co.,Ltd
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +6.18% | 0.15% | 11 M€ | |
| 0.00% | 0.1% | 0 M€ | |
| +2.46% | 0.01% | 33,076 M€ | |
| +2.76% | 0.01% | 32 M€ | |
| +0.98% | 0% | 864 M€ | |
| +0.90% | 0% | 64 M€ | |
| +0.46% | 0% | 87 M€ | |
| +0.85% | 0% | 661 M€ | |
| +0.22% | 0% | 186 M€ | |
| +0.46% | 0% | 34 M€ | |
| +6.00% | 0% | 20 M€ | |
| +0.25% | 0% | 85 M€ | |
| 0.00% | 0% | 14 M€ |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
- ETFs Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Select your edition
All financial news and data tailored to specific country editions
